Literature DB >> 23550604

Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling.

Ablajan Mahmut1, Marie-Chloé Boulanger, Dominique Fournier, Christian Couture, Sylvain Trahan, Sylvain Pagé, Benoît Arsenault, Jean-Pierre Després, Philippe Pibarot, Patrick Mathieu.   

Abstract

BACKGROUND: Calcific aortic valve disease (CAVD) is a chronic disorder characterized by a fibrocalcific remodelling. It is suspected that lipid retention within the aortic valve may be one important mechanism participating to aortic valve remodelling. Lipoprotein lipase (LPL) is implicated in lipid metabolism and may play a role in lipid retention within the aortic valve.
METHODS: In 57 patients, CAVD were analysed for the expression of LPL by q-PCR and immunohistochemistry. Expression of oxidized-LDL (ox-LDL) and decorin was also documented. In addition, a complete blood profile, including the size of LDL and high-density lipoprotein (HDL) particles, were performed to find associations between the blood lipid profile and expression of ox-LDL and LPL within CAVD.
RESULTS: Immunohistochemistry studies revealed that LPL was expressed in stenotic aortic valves as a diffuse staining and also in dense cellular areas where macrophages were abundant. Expression of LPL co-localized with decorin and ox-LDL. In turn, valves with higher amount of ox-LDL had elevated number of LPL transcripts. In addition, we documented that the small, dense HDL phenotype was associated with an elevated amount of ox-LDL and LPL transcripts within CAVD. Furthermore, expression of LPL was associated with several indices of fibrocalcific remodelling of the aortic valve.
CONCLUSION: Expression of LPL within CAVD is related to the amount of ox-LDL, which is, in turn, associated with the small, dense HDL phenotype. Lipid retention associated with smaller HDL particles may participate in the expression of LPL, whereby a fibrocalcific remodelling of the aortic valve is promoted.
© 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23550604     DOI: 10.1111/eci.12081

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

Review 1.  Potential drug targets for calcific aortic valve disease.

Authors:  Joshua D Hutcheson; Elena Aikawa; W David Merryman
Journal:  Nat Rev Cardiol       Date:  2014-01-21       Impact factor: 32.419

Review 2.  Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk.

Authors:  Patrick Mathieu; Marie-Chloé Boulanger; Jean-Pierre Després
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

3.  Monocytes and Macrophages in Heart Valves: Uninvited Guests or Critical Performers?

Authors:  Sridhar Sraeyes; Duc H Pham; Terence W Gee; Joanna Hua; Jonathan T Butcher
Journal:  Curr Opin Biomed Eng       Date:  2018-03-05

Review 4.  Calcific aortic stenosis.

Authors:  Brian R Lindman; Marie-Annick Clavel; Patrick Mathieu; Bernard Iung; Patrizio Lancellotti; Catherine M Otto; Philippe Pibarot
Journal:  Nat Rev Dis Primers       Date:  2016-03-03       Impact factor: 52.329

5.  Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease.

Authors:  Florian Schlotter; Arda Halu; Shinji Goto; Mark C Blaser; Simon C Body; Lang H Lee; Hideyuki Higashi; Daniel M DeLaughter; Joshua D Hutcheson; Payal Vyas; Tan Pham; Maximillian A Rogers; Amitabh Sharma; Christine E Seidman; Joseph Loscalzo; Jonathan G Seidman; Masanori Aikawa; Sasha A Singh; Elena Aikawa
Journal:  Circulation       Date:  2018-07-24       Impact factor: 29.690

6.  Circulating and tissue matricellular RNA and protein expression in calcific aortic valve disease.

Authors:  Alexander P Kossar; Wanda Anselmo; Juan B Grau; Yichuan Liu; Aeron Small; Samuel L Carter; Lisa Salvador; Lei Zhao; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Nancy Rioux; Daniel J Rader; Robert J Levy; Giovanni Ferrari
Journal:  Physiol Genomics       Date:  2020-02-24       Impact factor: 3.107

Review 7.  Innate and Adaptive Immunity in Calcific Aortic Valve Disease.

Authors:  Patrick Mathieu; Rihab Bouchareb; Marie-Chloé Boulanger
Journal:  J Immunol Res       Date:  2015-05-03       Impact factor: 4.818

8.  The pathology and pathobiology of bicuspid aortic valve: State of the art and novel research perspectives.

Authors:  Patrick Mathieu; Yohan Bossé; Gordon S Huggins; Alessandro Della Corte; Philippe Pibarot; Hector I Michelena; Giuseppe Limongelli; Marie-Chloé Boulanger; Arturo Evangelista; Elisabeth Bédard; Rodolfo Citro; Simon C Body; Mona Nemer; Frederick J Schoen
Journal:  J Pathol Clin Res       Date:  2015-06-24

Review 9.  Cellular Mechanisms of Valvular Thickening in Early and Intermediate Calcific Aortic Valve Disease.

Authors:  Pauli Ohukainen; Heikki Ruskoaho; Jaana Rysa
Journal:  Curr Cardiol Rev       Date:  2018

10.  MicroRNA-134 Promotes the Development of Atherosclerosis Via the ANGPTL4/LPL Pathway in Apolipoprotein E Knockout Mice.

Authors:  Qiong Ye; Guo-Ping Tian; Hai-Peng Cheng; Xin Zhang; Xiang Ou; Xiao-Hua Yu; Ru-Qi Tan; Feng-Yun Yang; Duo Gong; Chong Huang; Yan-Jun Pan; Jie Zhang; Ling-Yan Chen; Zhen-Wang Zhao; Wei Xie; Liang Li; Min Zhang; Xiao-Dan Xia; Xi-Long Zheng; Chao-Ke Tang
Journal:  J Atheroscler Thromb       Date:  2017-09-01       Impact factor: 4.928

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.